Please assess the completion status of the following clinical trial:

Trial Title: Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children 2-12 years requiring laceration repair using suturing and use of injected lidocaine~Exclusion Criteria:~* Administration in ER of analgesia or sedation other than acetaminophen or ibuprofen prior to enrolment~* ASA of III or greater~* Multi-system trauma~* Severe neurologic impairment or non-verbal autism, known allergy/hypersensitivity to lidocaine or midazolam~* Parent/guardian does not speak one of French or English~* No parent/guardian present during procedure

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 12 Years
- Healthy Volunteers: t

Study Arms:
- Intranasal Saline (Type: PLACEBO_COMPARATOR): 0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
- Intranasal Midazolam (Type: ACTIVE_COMPARATOR): 0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300

Based on this trial design, predict the completion outcome and termination type (if applicable).